The Report Global and China DNA Sequencing Industry Research Report, 2014-2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz

Albany, NY -- (SBWire) -- 01/14/2015 --DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a broad range of fields, including medicine, biology, geology, and agriculture.

View Full Report
http://www.marketresearchreports.biz/analysis/225746

With the advancement of DNA sequencing technology and dramatic decline in sequencing costs, DNA sequencing is increasingly showing its market potential in noninvasive detection, disease diagnosis, and personalized treatment. In 2013, the market size of global DNA sequencing (including equipment and consumables, service and workflow, etc.) approximated USD4.6 billion, up around 26% from the previous year. It is projected that by 2017 this figure will reach USD10.096 billion, exceeding USD10 billion for the first time.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/225746

Ever since 1975, DNA sequencing technology has been through four generations, but the fourth-generation technology—Nanopore sequencing is still under development. Due to technologies and costs, the second-generation high-throughput sequencers are the mainstream sequencing platform around the world, with its total number occupying over 95% of next-generation DNA sequencers worldwide.

The upstream sectors of DNA sequencing industry are extremely robust, with the global market dominated by the second-generation DNA sequencing enterprises including Illumina, Thermo Fisher Scientific (through Life Technologies), Roche and the third-generation sequencing enterprises such as Pacific Biosciences. A review of these giants' development history shows that mergers and acquisitions are the main driving forces behind the great market power. In February 2014, Roche acquired Life Technologies for USD13.6 billion, making it the industry giant second only to Illumina.

Explore All Latest Published Reports By Research In China
http://www.marketresearchreports.biz/publisher/67

In China, the upstream sectors of DNA sequencing industry are virtually monopolized by foreign giants. BGI is the leader in China's DNA sequencing service, and its second-generation DNA sequencers top the global chart in number. However, two of its sequencers—HiSeq 2000 and Ion Proton were entirely from Illumina and Life Technologies. In March 2013, BGI acquired Complete Genomics, a sign that BGI formally ventured into the upstream sectors of DNA sequencing industry. In June 2014, BGI's two products—BGISEQ-1000 and BGISEQ-100 became the first second-generation DNA sequencers registered in China.

It is expected, however, that within the next five years the weak position of Chinese enterprises in upstream sectors will remain unchanged except for the epic M&A.

Related Reports

China Pharmaceutical Excipients Industry Report, 2014-2017

View Full Report
http://www.marketresearchreports.biz/analysis/232334

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/232334

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

China Recombinant Protein Drug Industry Report, 2014-2017

View Full Report
http://www.marketresearchreports.biz/analysis/232274

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/232274

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us:
Office: State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: 518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz